- Home
- EA vs TAK Comparison
EA vs TAK Comparison
Compare EA & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EA
- TAK
- Stock Information
- Founded
- EA 1982
- TAK 1781
- Country
- EA United States
- TAK Japan
- Employees
- EA N/A
- TAK 49281
- Industry
- EA Computer Software: Prepackaged Software
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- EA Technology
- TAK Health Care
- Exchange
- EA Nasdaq
- TAK Nasdaq
- Market Cap
- EA 41.4B
- TAK 41.5B
- IPO Year
- EA N/A
- TAK N/A
- Fundamental
- Price
- EA $147.80
- TAK $13.10
- Analyst Decision
- EA Buy
- TAK
- Analyst Count
- EA 17
- TAK 0
- Target Price
- EA $165.59
- TAK N/A
- AVG Volume (30 Days)
- EA 2.2M
- TAK 1.6M
- Earning Date
- EA 02-04-2025
- TAK 01-30-2025
- Dividend Yield
- EA 0.51%
- TAK 4.84%
- EPS Growth
- EA 7.92
- TAK 49.73
- EPS
- EA 3.89
- TAK 1.27
- Revenue
- EA $7,409,000,000.00
- TAK $31,732,209,416.00
- Revenue This Year
- EA $4.88
- TAK $4.41
- Revenue Next Year
- EA $5.86
- TAK $1.09
- P/E Ratio
- EA $37.97
- TAK $20.56
- Revenue Growth
- EA N/A
- TAK 9.43
- 52 Week Low
- EA $124.92
- TAK $12.58
- 52 Week High
- EA $168.50
- TAK $15.08
- Technical
- Relative Strength Index (RSI)
- EA 26.56
- TAK 36.45
- Support Level
- EA $162.27
- TAK $12.98
- Resistance Level
- EA $167.71
- TAK $13.42
- Average True Range (ATR)
- EA 2.94
- TAK 0.15
- MACD
- EA -2.54
- TAK -0.05
- Stochastic Oscillator
- EA 5.14
- TAK 10.85
About EA Electronic Arts Inc.
Electronic Arts is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, EA Sports FC (formerly FIFA), Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.